Business Wire

Synaps Chooses iProov’s Genuine Presence Assurance™ for Secure Onboarding and KYC in Cryptocurrency

Share

iProov, the world leader in facial biometric authentication technology, has been chosen by Synaps to support the company’s global expansion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005864/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

iProov's Genuine Presence Assurance™ enables organizations to verify that an online user is the right person, a real person, and that they are authenticating right now. (Photo: Business Wire)

Synaps, the Paris-based provider of digital identity services for cryptocurrency, is implementing iProov’s Genuine Presence Assurance technology. This will verify the identity of users during the onboarding process using biometric facial authentication.

Genuine Presence Assurance uses a simple, passive face scan to assure that an individual is the right person, matching the identity in a trusted identity document. It also verifies that the user is a real person and not a presentation attack using a photo or mask, and that they are authenticating right now and not a digitally injected attack using a deepfake or other synthetic media.

“This is about using cutting-edge technology to mitigate risk and better protect our customers’ interests,” said Florian Le Goff, Synaps Founder and CEO. “The use of deepfakes is a very real threat and we need to prevent criminals from using them to create fake identities for Know Your Customer (KYC) checks.”

“With its face biometrics, iProov is helping us to ensure that we’re dealing with genuine users while providing a super-simple onboarding process to keep our user completion rates high and minimize drop-off rates.”

Individuals will benefit from a simplified user experience, and greater control of their data and where that data is being shared across the Synaps network. By completing the necessary Know Your Customer (KYC) procedure once, the user can then access multiple platforms without needing to repeat the process.

Le Goff continued: “In the physical world, individuals go through KYC maybe once or twice a year at most. In cryptocurrency, all of the services need to know who you are, so KYC has to be repeated. It’s like going to an airport and having to show your passport over and over again, every 100 meters.

“Synaps enables our users to do KYC once and get access to multiple platforms. iProov helps us ensure that the one-time KYC is completed in line with government-grade security levels. They’re also really good to work with: they know what they’re doing and we like working with them.”

Synaps offers decentralized identity management services to both individuals and cryptocurrency exchanges. It specializes in KYC (Know Your Customer) and KYB (Know Your Business) identity verification, with customers coming from many industries, including banking, insurance, cryptocurrency and other financial services.

The iProov process maximizes inclusivity by eliminating the need for users to follow instructions and by being available across all platforms and devices with a front-facing camera.

Andrew Bud, iProov CEO, said; “We’re very pleased to be working with Synaps. Too many organizations take unnecessary risks on security to protect their completion rates, while others lose business with complex online onboarding procedures. iProov and Synaps share a commitment to delivering security and compliance in a way that is effortless for the user.”

About iProov

Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance and Genuine Presence Assurance, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sarah Merker
sarah.merker@iproov.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye